ArticleFrontiers in oncology2025
An innovative hippocampal-sparing whole-brain radiotherapy planning approach via the Halcyon system: achieving lower hippocampal doses.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the feasibility and dosimetric benefits of Halcyon-based coplanar dual-arc volumetric modulated arc therapy (VMAT) for hippocampal-avoidance whole brain radiotherapy (HA-WBRT). Methods: Twenty-one HA-WBRT patients were replanned using dual-arc VMAT (collimator 23°/293°) on Halcyon and Truebeam. The planning target volume (PTV) was segmented into three substructures and optimized with different weight parameters. Dosimetric parameters of PTV, monitor units (MUs), does to organs-at-risk(OARs), hippocampal normal tissue complication probability (NTCP) and gamma passing rate were recorded. Results: All plans met RTOG 0933 criteria. The Halcyon plans demonstrated significantly better homogeneity index (HI) and V Conclusions: Under the innovative planning approach, redefined hippocampal-sparing radiotherapy using Halcyon system, providing superior prescription dose coverage, improved OAR sparing, and reduced hippocampal NTCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.